CGON (CG Oncology) Operating Cash Flow per Share : $-1.16 (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Operating Cash Flow per Share?

CG Oncology's operating cash flow per share for the three months ended in Mar. 2025 was $-0.38. CG Oncology's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.16.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -45.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for CG Oncology's Operating Cash Flow per Share or its related term are showing as below:

CGON' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -45.9 Med: -45.9 Max: -45.9
Current: -45.9

During the past 4 years, CG Oncology's highest 3-Year average Operating Cash Flow per Share Growth Rate was -45.90% per year. The lowest was -45.90% per year. And the median was -45.90% per year.

CGON's 3-Year OCF Growth Rate is ranked worse than
91.71% of 1219 companies
in the Biotechnology industry
Industry Median: 9.2 vs CGON: -45.90

CG Oncology Operating Cash Flow per Share Historical Data

The historical data trend for CG Oncology's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Operating Cash Flow per Share Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

-0.41

-7.97

-0.72

-1.26

CG Oncology Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial						-0.55	-0.24	-0.24	-0.30	-0.38

Competitive Comparison of CG Oncology's Operating Cash Flow per Share

For the Biotechnology subindustry, CG Oncology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CG Oncology's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

CG Oncology Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

CG Oncology's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-78.713	/	62.497
	=	-1.26

CG Oncology's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-29.277	/	76.188
	=	-0.38

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.16

CG Oncology Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of CG Oncology's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.